期刊文献+

射频治疗无排卵性功血内膜中Survivin的表达及意义 被引量:1

下载PDF
导出
摘要 目的射频治疗无排卵性功血前后观察内膜组织病理改变特点,生存素(Survivin)变化,循证射频热凝固治疗功血的机制。方法 56例无排卵功血患者射频治疗前后3个月诊刮。取其内膜组织行HE染色观察病理变化,免疫组化检测Survivin水平。结果 Survivin在正常子宫内膜、增生期样子宫内膜,单纯性增生和复杂性增生子宫内膜组织中的阳性表达率随病变程度的加重依次升高。射频治疗3个月后子宫内膜间质坏死,肉芽组织增生修复坏死区域,部分腺体腺腔塌陷、闭塞消失,大量纤维组织增生。患者子宫内膜组织中Survivin的阳性表达率明显低于治疗前。结论 Survivin在无排卵性功血的发病中发生效应,这提示可能通过子宫内膜局部调节因子影响子宫内膜的出血过程。射频治疗后子宫内膜间质细胞坏死,纤维组织增生。凝固后的内膜为肉芽组织替代,不再发生周期性脱落,Survivin的表达较治疗前明显下降,是射频治疗功血的机制。
作者 崔丽
机构地区 天津市西青医院
出处 《哈尔滨医药》 2011年第1期29-30,共2页 Harbin Medical Journal
  • 相关文献

参考文献8

  • 1乐杰.妇产科学[M]5版[M].北京:人民卫生出版社,2001.129.
  • 2Taylor R N,Lebovie D J,HomungD.et al.Endocrine and paracrine regulation of endometrial angiogenesis[J].Ann N Y Acad Sci,2001,943:109-121.
  • 3赖银璇,李英勇,王芳.Survivin与卵巢癌的关系[J].现代肿瘤医学,2004,12(4):371-372. 被引量:4
  • 4Takai N,Miyazaki T,Nishida M,et al.Survivin expression correlates with clinical stage,histological grade,invasive behavior and sur-vival rate in endometrial carcinoma[J].Cancer Lett,2002,184(1):105-116.
  • 5Lehner R,Enomoto T,McGregar GA,et al.Correlation of survivin mRNA detection with hislological diagnosis in normal endometrium and endometrial carcinoma[J].Acta Obstet Gynecol Scand,2002,81(2):162-167.
  • 6Tarkowski R,W,Wojcierowski J,Polak G,el a1.Expression of t he survivin gene in normal and hyperplastie endomet rium[J].Ginekol Pol,2000,71(9):1226.
  • 7戴良图,曾敏华,许恒.子宫肌瘤射频治疗对卵巢功能的影响[J].海军医学杂志,2003,24(4):309-311. 被引量:20
  • 8耿爱芝,王振锋,刘秋红,汪桂贞.射频消融去除子宫内膜治疗功能失调性子宫出血30例分析[J].临床医药实践,2005,14(6):432-433. 被引量:1

二级参考文献17

  • 1[1]FRIEDMAN A S, BARBIERI R L, DOUBILET P M, et al. A, randomized,double blindtrial of agonadotropin relensing-hormone agonist (leuprolide) with or without medroxyprogestestreone.acetate in the treatment of leiomyomata uteri[J]. Fertil Steril, 1988, 49(4): 404-409.
  • 2[2]MURPHY A A, KETTEL L M, MORALES A J, etal. Regression of uterint leiomomata in response to the antiprogestront Ru486[J]. J Clin Endocrinol Metab, 1993, 76(6): 513-517.
  • 3[1]Ambrosini G, Adida C. A novel anti-apoptosis gene, surivin, expressed in cancer and 1ymphoma[J].Nat Med,1997,3(8):917~921.
  • 4[2]Muchmore SW, Chen J, Jakob C,et al.Crystal structure and mutagenic analysis of the inhibitor of apoptosis protein survivin[J].Mol Cell,2000 ,6(1):173~182.
  • 5[3]Mahotka C,Wenzel M,Springer E,et al.Survivin-delta Ex3 and sur vivin-2B:two novel splice variants of the apoptosis inhibitors survivin with different antiapoptotic properties[J].Cancer Res,1999,59(24):6097~6102.
  • 6[4]Tamm I,Wang Y,Sausville E,et al.IAP-family protein survivin in hibits caspase activity and apoptosis induced by Fas(CD95),Bax,caspases,and anticancer drugs[J].Cancer Res,1998,58(23):5315~5320.
  • 7[5]Suzuki A, Ito T,Kawano H,et al.survivin initiates procaspase 3 /P21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death[J].Oncogene,2000,19(10):1346~1353.
  • 8[6]Li F,Ambrosini G, Chu EY,et al.Control of apoptosis and mitotic spindle checkpoint by Survivn[J].Nature,1998,369(6711):580~584.
  • 9[7]Li F,Altieri DC.Transcriptional analysis of human survivin gene expression[J].Biochem.J,1999,344:305~311.
  • 10[8]Cohen C,Lohmann CM,Cotsonis G,et al.Survivin expression in ova rian carcinoma: correlation with apoptotic markers and prognosis[J].Mod Patho l,2003,16(6):574~583.

共引文献223

同被引文献29

引证文献1

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部